Cargando…

The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety

BACKGROUND: Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage. METHODS: We used the Permanent Sample of Bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Fonteneau, Laure, Ragot, Marine, Parent du Châtelet, Isabelle, Guthmann, Jean-Paul, Lévy-Bruhl, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676816/
https://www.ncbi.nlm.nih.gov/pubmed/26654908
http://dx.doi.org/10.1186/s12889-015-2575-7
_version_ 1782405234544345088
author Fonteneau, Laure
Ragot, Marine
Parent du Châtelet, Isabelle
Guthmann, Jean-Paul
Lévy-Bruhl, Daniel
author_facet Fonteneau, Laure
Ragot, Marine
Parent du Châtelet, Isabelle
Guthmann, Jean-Paul
Lévy-Bruhl, Daniel
author_sort Fonteneau, Laure
collection PubMed
description BACKGROUND: Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage. METHODS: We used the Permanent Sample of Beneficiaries which was, at the time of the study, a representative sample of 1/97(th) health insurance beneficiaries of the main Social Security scheme, the General Health Insurance Scheme, covering approximately 77 % of the French resident population. We estimated HPV vaccination coverage among girls born between 1995 and 1999 at their 15(th), 16(th) and 17(th) birthday. RESULTS: The coverage for complete vaccination among 16 years old girls decreased from 26.5 % in the first semester of 2011 to 18.6 % in the first semester of 2014. CONCLUSIONS: HPV vaccination coverage was already low in 2011 and continued to decrease thereafter. Vaccines reimbursement data allowed us to reactively monitor the impact of the controversy on vaccination coverage and design counteracting measures.
format Online
Article
Text
id pubmed-4676816
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46768162015-12-13 The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety Fonteneau, Laure Ragot, Marine Parent du Châtelet, Isabelle Guthmann, Jean-Paul Lévy-Bruhl, Daniel BMC Public Health Research Article BACKGROUND: Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage. METHODS: We used the Permanent Sample of Beneficiaries which was, at the time of the study, a representative sample of 1/97(th) health insurance beneficiaries of the main Social Security scheme, the General Health Insurance Scheme, covering approximately 77 % of the French resident population. We estimated HPV vaccination coverage among girls born between 1995 and 1999 at their 15(th), 16(th) and 17(th) birthday. RESULTS: The coverage for complete vaccination among 16 years old girls decreased from 26.5 % in the first semester of 2011 to 18.6 % in the first semester of 2014. CONCLUSIONS: HPV vaccination coverage was already low in 2011 and continued to decrease thereafter. Vaccines reimbursement data allowed us to reactively monitor the impact of the controversy on vaccination coverage and design counteracting measures. BioMed Central 2015-12-12 /pmc/articles/PMC4676816/ /pubmed/26654908 http://dx.doi.org/10.1186/s12889-015-2575-7 Text en © Fonteneau et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Fonteneau, Laure
Ragot, Marine
Parent du Châtelet, Isabelle
Guthmann, Jean-Paul
Lévy-Bruhl, Daniel
The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety
title The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety
title_full The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety
title_fullStr The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety
title_full_unstemmed The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety
title_short The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety
title_sort use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676816/
https://www.ncbi.nlm.nih.gov/pubmed/26654908
http://dx.doi.org/10.1186/s12889-015-2575-7
work_keys_str_mv AT fonteneaulaure theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety
AT ragotmarine theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety
AT parentduchateletisabelle theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety
AT guthmannjeanpaul theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety
AT levybruhldaniel theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety
AT fonteneaulaure useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety
AT ragotmarine useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety
AT parentduchateletisabelle useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety
AT guthmannjeanpaul useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety
AT levybruhldaniel useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety